Unbalanced production of interleukin-5 and interleukin-2 in children with atopic dermatitis

被引:19
作者
Yamamoto, S [1 ]
Hamasaki, Y [1 ]
Ishii, E [1 ]
Ichimaru, T [1 ]
Miyazaki, S [1 ]
机构
[1] SAGA PREFECTURAL HOSP KOSEIKAN,SAGA,JAPAN
关键词
D O I
10.1016/S1081-1206(10)63241-3
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Cytokines, such as interleukin (IL)-5, produced by T helper type 2 (Th2) cells appear to play an important role in the inflammatory processes associated with atopic dermatitis, The roles of cytokines produced by Th1 cells remain controversial. Objective: We examined IL-5 and IL-2 mRNA abundance in and protein production by peripheral blood mononuclear cells (PBMCs) from patients with atopic dermatitis and compared those from controls. Methods: Peripheral blood mononuclear cells were isolated from six children with atopic dermatitis and six control children, and stimulated with both phytohemaggulutinin (PHA) and phorbol 12-myristate 13-acetate (PMA). The abundance of IL-5 and IL-2 mRNA in PBMCs was measured by reverse transcription-polymerase chain reaction analysis. The production of IL-5 and IL-2 by PBMCs was also determined by enzyme-linked immunosorbent assay. Results: After incubation with PHA and PMA, PBMCs from atopic children showed significantly higher IL-5 mRNA abundance (P < .05) and IL-5 production (P < .01), as well as a lower amount of IL-2 mRNA (P = .056) and IL-2 production (P < .05) than those from healthy controls. The time course of changes in IL-5 mRNA abundance induced by PHA and PMA in PBMCs from atopic children differed markedly from that observed with healthy controls, whereas the time course of changes in IL-2 mRNA abundance were similar between the two groups. Conclusions: The increased IL-5 and decreased IL-2 production observed with PBMCs from children with atopic dermatitis may underlie the activation of eosinophils and high serum immunoglobulin E concentrations also apparent in such individuals, An imbalance in the number and activity of Th1 and Th2 cells is likely to be responsible for the abnormal pattern of cytokine production in atopic dermatitis.
引用
收藏
页码:517 / 523
页数:7
相关论文
共 31 条
[1]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[2]   ATOPIC-DERMATITIS - RECENT TRENDS IN PATHOGENESIS AND THERAPY [J].
COOPER, KD .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (01) :128-137
[3]   CD4 T-LYMPHOCYTE ACTIVATION IN ASTHMA IS ACCOMPANIED BY INCREASED SERUM CONCENTRATIONS OF INTERLEUKIN-5 - EFFECT OF GLUCOCORTICOID THERAPY [J].
CORRIGAN, CJ ;
HACZKU, A ;
GEMOUENGESAETH, V ;
DOI, S ;
KIKUCHI, Y ;
TAKATSU, K ;
DURHAM, SR ;
KAY, AB .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (03) :540-547
[4]  
DOI S, 1994, CLIN EXP ALLERGY, V24, P854, DOI 10.1111/j.1365-2222.1994.tb01808.x
[5]  
GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110
[6]  
HUANG SK, 1995, J IMMUNOL, V155, P2688
[7]   DECREASED INTERFERON-GAMMA AND INCREASED INTERLEUKIN-4 PRODUCTION IN ATOPIC-DERMATITIS PROMOTES IGE SYNTHESIS [J].
JUJO, K ;
RENZ, H ;
ABE, J ;
GELFAND, EW ;
LEUNG, DYM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 90 (03) :323-331
[8]   MESSENGER-RNA EXPRESSION OF THE CYTOKINE GENE-CLUSTER, INTERLEUKIN-3 (IL-3), IL-4, IL-5, AND GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR, IN ALLERGEN-INDUCED LATE-PHASE CUTANEOUS REACTIONS IN ATOPIC SUBJECTS [J].
KAY, AB ;
YING, S ;
VARNEY, V ;
GAGA, M ;
DURHAM, SR ;
MOQBEL, R ;
WARDLAW, AJ ;
HAMID, Q .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (03) :775-778
[9]   INTERLEUKIN-12 REGULATES THE PROLIFERATION OF TH1, BUT NOT TH2 OR TH0, CLONES [J].
KENNEDY, MK ;
PICHA, KS ;
SHANEBECK, KD ;
ANDERSON, DM ;
GRABSTEIN, KH .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (10) :2271-2278
[10]   ANALYSIS OF CYTOKINE TRANSCRIPTS IN THE BRONCHOALVEOLAR LAVAGE CELLS OF PATIENTS WITH ASTHMA [J].
KRISHNASWAMY, G ;
LIU, MC ;
SU, SN ;
KUMAI, M ;
XIAO, HQ ;
MARSH, DG ;
HUANG, SK .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1993, 9 (03) :279-286